<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946813</url>
  </required_header>
  <id_info>
    <org_study_id>PRP</org_study_id>
    <nct_id>NCT03946813</nct_id>
  </id_info>
  <brief_title>The Efficacy of Platelets Rich Plasma for Ovarian Rejuvenation</brief_title>
  <official_title>The Efficacy of Platelets Rich Plasma (PRP) for Ovarian Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Kindy College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>High Institute for Infertility Diagnosis and Assisted Reproductive Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Kindy College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, an increased approach has appeared in the use of autologous blood products
      to assist tissue and organ healing. Application of platelet rich plasma (PRP) has emerged as
      a potential solution for infertile women with poor ovarian reserve in reproductive specialty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quantitative and qualitative functional improvement of ovarian function has been reported in
      several studies after using autologous PRP in a reproductive field. Ovarian rejuvenation,
      stimulating the ovaries to produce new eggs after injecting PRP, can offer hope for renewed
      fertility to women with poor reserve volume, advanced maternal age, or either naturally
      occurring or premature menopause. But, these encouraging results should be supported by
      several new studies.

      This study aimed to estimate the efficacy of trans-vaginal ovarian injection with PRP in
      rejuvenates ovaries in woman with poor ovarian reserve, and to assess any association of some
      women variables (age, menstrual status, parity, BMI) as predicting factors in success of
      ovarian injection with PRP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Follicle-stimulating hormone (FSH) concentration</measure>
    <time_frame>4 weeks</time_frame>
    <description>Before after intervention measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-MÃ¼llerian hormone (AMH) concentration</measure>
    <time_frame>4 weeks</time_frame>
    <description>Before after intervention measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antral follicles numbers</measure>
    <time_frame>4 weeks</time_frame>
    <description>Before after intervention measurement</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Poor ovarian reserve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infertile women with poor ovarian reserve</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous PRP preparation</intervention_name>
    <description>For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide</description>
    <arm_group_label>Poor ovarian reserve</arm_group_label>
    <other_name>Plasma Rich Platelets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Menopause or peri-menopause under the age of 50.

          2. Premature ovarian insufficiency which is ovarian failure before the age of 40.

          3. Woman with primary ovarian failure of any cause.

        Exclusion Criteria:

          1. A previous injection with any medication, plasma, or PRP

          2. Invisible or difficult access ovaries.

          3. Medical disease or unfit for anesthesia patient.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Infertile women</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thuraya H Abdulla, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Arab Board for Medical Specializations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>High Institute for Infertility Diagnosis and Assisted Reproductive Technologies</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <results_reference>
    <citation>A</citation>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>October 26, 2019</last_update_submitted>
  <last_update_submitted_qc>October 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Kindy College of Medicine</investigator_affiliation>
    <investigator_full_name>Yousif Abdulraheem</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ovarian Rejuvenation , Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data will be managed confidentially</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

